# US 2012/0251529 A1 · Anti-cea antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251529 A1
- Document ID: US20120251529A1
- Status: Published application
- Kind: A1
- Application number: 13/408,171
- Filed: 2012-02-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-02
- Assignees: Roche Glycart AG
- Inventors: Thomas U. Hofer; Ralf Hosse; Ekkehard Moessner; Pablo Umana
- Web page: https://patentgrep.com/patent/US20120251529A1

## CPC

- C07K 16/42: against immunoglobulins
- A61K 39/39566: {against immunoglobulins, e.g. anti-idiotypic antibodies}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/3007: {Carcino-embryonic Antigens}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.

## Claims

### Claim 1

An isolated antibody which binds membrane-bound CEA, wherein the antibody comprises a heavy chain variable region comprising:
a heavy chain CDR1 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:12,
a heavy chain CDR2 selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24,
a heavy chain CDR3 selected from the group consisting of SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219 SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, and SEQ ID NO:224, and
a light chain CDR1 selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45, and
a light chain CDR2 selected from the group consisting of SEQ ID NO:46, and SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, and SEQ ID NO:55, and
a light chain CDR3 of SEQ ID NO:56.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the heavy chain variable region comprises:
the heavy chain CDR1 of SEQ ID NO:1,
the heavy chain CDR2 of SEQ ID NO:13,
a heavy chain CDR3 selected from the group consisting SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219 SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, and SEQ ID NO:224; and
wherein the light chain variable region comprises:
the light chain CDR1 of SEQ ID NO:39,
the light chain CDR2 of SEQ ID NO:49, and
the light chain CDR3 of SEQ ID NO:56.

### Claim 3 (depends on 2)

The antibody of claim 2, wherein the antibody comprises the framework residues of CH1A1A (SEQ ID NO: 261) or CH1A1B (SEQ ID NO: 262).

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody is stable at a temperature that is at least 0.5, 1.0, 1.5, or 2.0 degree Celcius higher than PR1A3 antibody or a humanized version of PR1A3 antibody.

### Claim 5 (depends on 4)

The antibody of claim 4, wherein the PR1A3 antibody or humanized version of PR1A3 antibody is a humanized version of PR1A3 antibody which comprises the heavy chain variable region CH7A (SEQ ID NO:101) and the light chain variable region 2F1 (SEQ ID NO: 209).

### Claim 6 (depends on 4)

The antibody of claim 4, wherein the increase in stability is measured using a dynamic light scattering assay.

### Claim 7

An isolated antibody which binds membrane-bound CEA, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, and SEQ ID NO: 247 and a light chain variable region comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 209, and wherein the antibody has at least about 2-fold increase in stability as compared to PR1A3 or a humanized version of PR1A3.

### Claim 8

An isolated antibody which binds membrane-bound CEA, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, and SEQ ID NO: 247 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 209.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the antibody comprises an Fc region that has been glycoengineered.

### Claim 10 (depends on 9)

The antibody of claim 9, wherein at least about 20% to about 100% of the N-linked oligosaccharides in the Fc region are nonfucosylated.

### Claim 11 (depends on 9)

The antibody of claim 9, wherein at least about 20% to about 100% of the N-linked oligosaccharides in the Fc region are bisected.

### Claim 12 (depends on 9)

The antibody of claim 9, wherein at least about 20% to about 50% of the N-linked oligosaccharides in the Fc region are bisected, nonfucosylated.

### Claim 13 (depends on 9)

The antibody of claim 9, wherein the antibody has at least one increased effector function.

### Claim 14 (depends on 13)

The antibody of claim 13, wherein the at least one increased effector function is selected from the group consisting of: increased Fc receptor binding affinity, increased antibody-mediated cellular cytotoxicity (ADCC), increased binding to NK cells, increased binding to macrophages, increased binding to monocytes, increased binding to polymorphonuclear cells, direct signaling inducing apoptosis, increased dendritic cell maturation, and increased T cell priming.

### Claim 15 (depends on 14)

The antibody of claim 14, wherein the antibody has an increase in ADCC of at least about 40% to about 100% as compared to the non-glycoengineered parent antigen binding molecule.

### Claim 16 (depends on 1)

An isolated polynucleotide encoding the antibody of claim 1.

### Claim 17 (depends on 16)

A vector comprising the polynucleotide of claim 16.

### Claim 18 (depends on 17)

A host cell comprising the vector of claim 17.

### Claim 19 (depends on 14)

A composition comprising the antibody of claim 14 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method of inducing cell lysis of a tumor cell, the method comprising contacting the tumor cell with the antibody of any of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the tumor cell is selected from the group consisting of a colorectal cancer cell, NSCLC (non-small cell lung cancer), gastric cancer cell, pancreatic cancer cell and breast cancer cell.

### Claim 22 (depends on 20)

The method of claim 20, wherein the cell lysis is induced by antibody dependent cell cytotoxicity of the antibody.

### Claim 23 (depends on 1)

A method of treating a subject having a cancer that abnormally expresses CEA, the method comprising administering to the subject a therapeutically effective amount of the antibody of claim 1.

### Claim 24 (depends on 24)

The method of claim 24, wherein the antibody is administered in combination with chemotherapy or radiation therapy.
